[Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma]
- PMID: 18241575
[Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma]
Abstract
Objectives: To study the expression of Polo-like kinase 1 (PLK1) and E-cadherin in the tissues of hepatocellular carcinoma, and to discuss the relationship between them and clinical-pathological features, and to evaluate their prognostic value of hepatocellular carcinoma after liver transplantation.
Methods: mRNA and protein expression of PLK1, E-cadherin were detected by RT-PCR and immunohistochemistry method respectively, the correlations of them with clinical-pathological data, tumor free time, recurrence rate were compared and analyzed.
Results: The mRNA expression was observed in 90.0% for PLK1 and 96.0% for E-cadherin, and higher in cancerous' tissues than paracancerous' of all cases for PLK1 but no trend for E-cadherin. The positive and decreased expression rate for PLK1 and E-cadherin was observed in 60.0% and 50.0% respectively, the positive PLK1 expression was correlated with preoperative serum alpha-fetoprotein (AFP) only (chi2 = 4.433, P = 0.035), while E-cadherin expression was associated with none of the clinical-pathological features. There was a correlation between the positive PLK1 and decreased E-cadherin expression (chi2 = 5.333, P = 0.021). PLK1 (P = 0.006), E-cadherin (P = 0.019) and larger tumor (P = 0.019), portal vein tumor thrombi (P = 0.030), Edmondson grading (P = 0.019), preoperative serum AFP (P = 0.020) were all correlated with recurrence rate under Kaplan-Meier analysis, while only PLK1 (RR = 3.104, P = 0.009) had significant difference under Cox regression analysis.
Conclusions: The positive PLK1 expression and the decreased E-cadherin expression indicate higher recurrence rate of HCC after liver transplantation, and PLK1 is a independent risk factor.
Similar articles
-
[Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].Zhonghua Wai Ke Za Zhi. 2006 May 1;44(9):603-8. Zhonghua Wai Ke Za Zhi. 2006. PMID: 16784653 Chinese.
-
[The expression and significance of heparanase and nm23-H1 in hepatocellular carcinoma].Zhonghua Yi Xue Za Zhi. 2002 Nov 25;82(22):1553-6. Zhonghua Yi Xue Za Zhi. 2002. PMID: 12609066 Chinese.
-
[Polo like kinase 1 expression and prognostic value in gastric carcinomas].Zhonghua Wei Chang Wai Ke Za Zhi. 2007 Jan;10(1):70-2. Zhonghua Wei Chang Wai Ke Za Zhi. 2007. PMID: 17253180 Chinese.
-
Gene signatures in hepatocellular carcinoma (HCC).Semin Cancer Biol. 2011 Feb;21(1):4-9. doi: 10.1016/j.semcancer.2010.09.002. Epub 2010 Sep 17. Semin Cancer Biol. 2011. PMID: 20851183 Free PMC article. Review.
-
Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis.Gene. 2019 Dec 30;721:144097. doi: 10.1016/j.gene.2019.144097. Epub 2019 Sep 4. Gene. 2019. PMID: 31493507
Cited by
-
Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.World J Gastroenterol. 2012 Jul 21;18(27):3527-36. doi: 10.3748/wjg.v18.i27.3527. World J Gastroenterol. 2012. PMID: 22826617 Free PMC article.
-
The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.Biosci Rep. 2017 Aug 31;37(4):BSR20170852. doi: 10.1042/BSR20170852. Epub 2017 Jul 19. Biosci Rep. 2017. PMID: 28724602 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous